Moreover, combination treatment exhibited a better therapeutic effect than PD-1 blockade alone, as signified by enhanced antitumor TAMs, higher proportion of macrophages expressing CXCL9, increased frequency of CD8+ T cells, and decreased tumor burden (Figures 7F, 7G, S9C, and S9D), suggesting a potential for the combination of PMX-53 and anti-PD-1 in OC immunotherapy. The gene discussed is CXCL9; the disease is neoplasm.